CORRESPONDENCE: RESEARCH CORRESPONDENCE
Intracoronary Delivery of Hematopoietic Bone Marrow Stem Cells and Luminal Loss of the Infarct-Related Artery in Patients With Recent Myocardial Infarction
Samer Mansour, MD,
Marc Vanderheyden, MD,
Bernard De Bruyne, MD, PhD,
Bart Vandekerckhove, MD, PhD,
Leen Delrue, PhD,
Inge Van Haute, MD, PhD,
Guy Heyndrickx, MD, PhD,
Stephane Carlier, MD, PhD,
Gaston Rodriguez-Granillo, MD,
William Wijns, MD, PhD and
Jozef Bartunek, MD, PhD*
* Cardiovascular Center Aalst, OLV Ziekenhuis, Moorselbaan 164, 9300 Aalst, Belgium (Email: Jozef.Bartunek{at}olvz-aalst.be).
To the Editor: Angiogenesis and atherogenesis share a number of pathways suggesting that interrelated tradeoffs might be inherent to therapies designed to enhance collateral formation and cardiac repair (1). This "Janus-like" effect on atherosclerosis progression was observed in several experimental models exposed to therapy with bone marrow stem cells (BMSCs) (1–4). A recent clinical study reported high rates of in-stent restenosis after BMSC mobilization (5). In our study (6), CD133+ enriched BMSC exerted beneficial effects on cardiac recovery in patients with reperfused myocardial infarction, but the restenosis rates were also higher as expected after intracoronary BMSC therapy (7–11). Hence, we investigated the effects of intracoronary CD133+ enriched BMSC on in-stent neointimal proliferation and distal atherosclerosis progression in patients with recent myocardial infarction treated with angioplasty using bare-metal stents.
Thirty-eight patients with acute myocardial infarction due to occlusion of the proximal left anterior descending coronary artery (LAD) were studied. The cell group consisted of 21 patients receiving intracoronary injection of CD133+ enriched BMSC and follow-up catheterization with quantitative coronary angiography (QCA) and coronary functional assessment with the pressure-derived fractional flow reserve (FFR) (12,13). The control group consisted of 17 patients matched for ejection fraction, infarction size, and location with control catheterization between 4 and 8 months after the infarction. Segmental QCA analysis was performed for the stented segment and non-stented portion of the mid LAD and distal LAD. Data are shown as mean ± SEM. Paired t test and unpaired t test were used as appropriate.
There were no differences in clinical and demographic characteristics between groups (not shown). Baseline angiographic and functional characteristics are shown in Table 1. At follow-up, no significant changes were noted in luminal diameters of the contralateral artery (CLA) of either group (from 2.66 ± 0.09 mm to 2.65 ± 0.10 mm in the cell group, and from 2.71 ± 0.14 mm to 2.78 ± 0.17 mm in the control group, both p = NS). In contrast, higher loss index of the stented segment in the cell group (–0.42 ± 0.07 vs. –0.22 ± 0.06, p < 0.05) was paralleled by a greater leftward shift in the cumulative distribution of the minimal luminal diameter (MLD) as compared with the control group (Fig. 1A). In non-stented segments, cumulative luminal loss of the reference diameter (RD) and MLD at the mid and distal segment of the infarct-related artery (IRA) were higher in the cell group (Fig. 1B) or in the subgroup of patients without significant in-stent restenosis, as compared with relevant control subjects (Fig. 1C). Significant distal de novo stenosis (>50% stenosis) was seen in two patients in the cell group and none in control subjects. In a subset of the cell group patients undergoing serial intravascular ultrasound study (n = 5), plaque burden significantly increased in the IRA (from 45.9 ± 4.3% to 56.3 ± 3.9%, p < 0.05) but remained unchanged in the CLA of the same patients (from 40.5 ± 1.3% to 40.3 ± 1.2%, p = NS).
View larger version (19K):
[in this window]
[in a new window]
|
Figure 1 (A) Cumulative distribution of the minimal luminal diameter (MLD) within the stented segment in cells patients (line) and control subjects (line with full dots) after stented angioplasty and at follow-up. (B) Luminal loss (LL) of the reference diameter (RD) and MLD of distal non-stented segments of the infarct related artery (IRA) in all patients. (C) Luminal loss of the RD and MLD of distal non-stented segments of the IRA in patients without in-stent restenosis (ISR–).
|
|
Luminal changes by QCA were associated with a significant decrease in FFR of the IRA in the cell group, with no change in the control group (–0.21 ± 0.05 vs. 0.01 ± 0.04, p < 0.05). In patients without in-stent restenosis, the cell group showed a higher decrease in FFR as compared with relevant control subjects (–0.13 ± 0.05 vs. 0.06 ± 0.03, p < 0.05). The cell group patients receiving  9 x 106 CD133+ cells showed larger luminal loss in the mid non-stented segment of the IRA as compared with patients receiving a lower number of cells (–0.87 ± 0.19 mm vs. –0.25 ± 0.21 mm, p < 0.05). The cell group patients with in-stent restenosis or a de novo stenosis showed lower systemic interleukin-10 levels (1.95 ± 0.96 ng/ml vs. 5.01 ± 1.82 ng/ml, p = 0.07) and higher vascular endothelial growth factor (VEGF)-A levels (215.5 ± 42.9 pg/ml vs. 86.3 ± 29.0 pg/ml, p < 0.05) as compared with the cell group patients without new lesion or restenosis. No differences in plasma interleukin-6, monocyte chemoattractant protein-1, and basic fibroblast growth factor levels between groups were observed (not shown).
Present data indicate that intracoronary injection of enriched BMSC is associated with greater in-stent proliferation and larger luminal loss in non-stented IRA segments that result in a significant decrease in pressure-derived FFR. These changes are consistent with decreased epicardial conductance of the IRA, owing to diffuse luminal loss and increased plaque burden. Our study suggests several mechanisms for the "Janus-like" effect. First, the total number of CD34+ or CD133+ cells in the cell suspension was higher than in previous studies (5–11), and patients with a higher number of injected CD133+ cells showed a larger luminal loss of distal non-stented segments. Hence, dose-dependent increase in local concentrations of pro-angiogenic molecules might have exacerbated pro-atherogenic effects. Second, cell-treated patients with in-stent restenosis or a de novo stenosis showed lower levels of interleukin-10 and higher levels of serum VEGF-A, suggesting disequilibrium between pro-atherogenic and anti-atherogenic factors as a predisposing factor. Nevertheless, local concentration of inflammatory cytokines or biological activity of CD133+ could provide further insights into these hypotheses. As an alternative mechanism, in-stent proliferation might be related to repetitive balloon occlusion at the time of the cell injection, albeit at low inflation pressure, by impairing ongoing re-endothelialization. Note that earlier studies (6,14) demonstrated immunological safety of immunomagnetic isolation with absence of human anti-mouse antibodies after stem cell enrichment in bone marrow transplant patients, which argues against immunological response as the underlying mechanism.
In conclusion, our findings of reduced luminal diameters and epicardial conductance of the IRA, as assessed from the pressure-derived FFR, seem to be consistent with a higher risk for atherosclerosis progression after intracoronary administration of enriched BMSC. Yet, these data were obtained from retrospective analysis; they lack randomized controls and systematic use of intravascular ultrasound imaging to track changes in the vascular wall. Future and ongoing randomized studies using intracoronary injection of enriched and unfractionated BMSC should define the risk and mechanisms of potential "Janus-like" effects on the epicardial coronary circulation.
 |
Footnotes
|
|---|
Please note: authors from the Cardiovascular Center (Drs. Bartunek, Vanderheyden, De Bruyne, Wijns, and Heyndrickx) are members of a non-profit organization that is a founding member of the start-up company Cardio3.
|
References
|
|---|
1. Epstein SE, Stabile E, Kinnaird T, Lee CW, Clavijo L, Burnett MS. Janus phenomenon. The interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis Circ Res 2004;109:2826-2831.2. Silvestre JS, Gojova A, Brun V, et al. Transplantation of bone marrow-derived mononuclear cells in ischemic apolipoprotein E-knockout mice accelerates atherosclerosis without altering plaque composition Circulation 2003;108:2839-2842.[Abstract/Free Full Text] 3. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis Nat Med 2002;8:403-409.[CrossRef][Web of Science][Medline] 4. Hu Y, Davison F, Zhang Z, Xu Q. Endothelial replacement and angiogenesis in arteriosclerotic lesions of allografts are contributed by circulating progenitor cells Circulation 2003;108:3122-3127.[Abstract/Free Full Text] 5. Kang HJ, Kim HS, Zhang SY, et al. Effects of intracoronary infusion of peripheral blood stem cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarctionthe MAGIC cell randomised clinical trial. Lancet 2004;363:751-756.[CrossRef][Web of Science][Medline] 6. Bartunek J, Vanderheyden M, Vandekerckhove B, et al. Intracoronary injection of CD133+ enriched bone marrow progenitors promotes cardiac recovery after recent myocardial infarction. Feasibility and safety Circulation 2005;112(Suppl 9):I178-I183. 7. Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation Circulation 2002;106:957-961.[Abstract/Free Full Text] 8. Assmus B, Schachinger V, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI) Circulation 2002;106:3009-3017.[Abstract/Free Full Text] 9. Fernandez-Aviles F, San Roman JA, Garcia-Frade J, et al. Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction Circ Res 2004;95:742-748.[Abstract/Free Full Text] 10. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarctionthe Boost randomised controlled clinical trial. Lancet 2004;364:141-148.[CrossRef][Web of Science][Medline] 11. Schachinger V, Assmus B, Britten MB, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarctionfinal one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004;44:1690-1699.[Abstract/Free Full Text] 12. De Bruyne B, Pijls NHJ, Bartunek J, et al. Fractional flow reserve in patients with prior myocardial infarction Circulation 2001;104:157-162.[Abstract/Free Full Text] 13. De Bruyne B, Hersbach F, Pijls NHJ, et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but "normal" coronary angiography Circulation 2001;104:2401-2406.[Abstract/Free Full Text] 14. Richel DJ, Johnsen HE, Canon J, et al. Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients Bone Marrow Transplant 2000;25:243-249.[CrossRef][Medline]
This article has been cited by other articles:
|
|
|
|
 
M. Tendera, W. Wojakowski, W. Ruzyllo, L. Chojnowska, C. Kepka, W. Tracz, P. Musialek, W. Piwowarska, J. Nessler, P. Buszman, et al.
Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial
Eur. Heart J.,
June 1, 2009;
30(11):
1313 - 1321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Chien, I. J. Domian, and K. K. Parker
Cardiogenesis and the Complex Biology of Regenerative Cardiovascular Medicine
Science,
December 5, 2008;
322(5907):
1494 - 1497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Burt, Y. Loh, W. Pearce, N. Beohar, W. G. Barr, R. Craig, Y. Wen, J. A. Rapp, and J. Kessler
Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases
JAMA,
February 27, 2008;
299(8):
925 - 936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dimmeler, J. Burchfield, and A. M. Zeiher
Cell-Based Therapy of Myocardial Infarction
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2008;
28(2):
208 - 216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Leone and F. Crea
Stem cells in acute myocardial infarction: the good, the bad, and the ugly
Eur. Heart J.,
December 2, 2006;
27(24):
2911 - 2913.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. W. van Laake, R. Hassink, P. A. Doevendans, and C. Mummery
Heart repair and stem cells
J. Physiol.,
December 1, 2006;
577(2):
467 - 478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
Top
References